Recently Launched!
Check out Investor Copilot custom GPT, which lets you enjoy ChatGPT functionality with recent financial information
Conversationally interact with ChatGPT to now analyze updated prices, technical indicators, financial statements, macro-economic/company news & more for Stocks, ETFs & Cryptos
Conversationally interact with ChatGPT to now analyze updated prices, technical indicators, financial statements, macro-economic/company news & more for Stocks, ETFs & Cryptos
[ASND] Ascendis Pharma A/S - Cost of Revenue
Data updated 2023-Jun-24 (Saturday)Note: Detailed Statistics for Cost of Revenue in Income Statement for Ascendis Pharma A/S [NASDAQ:ASND] with frequency distribution chart that analyze trends & history . Cost of Revenues includes direct cost associated with manufacturing and delivering product to customers. View Income Statement for broader context
Share
Quarterly Cost of Revenue values for Ascendis Pharma A/S are rounded to enhance readability
| 2023-Mar | 2022-Dec | 2022-Sep | 2022-Jun | 2022-Mar | 2021-Dec | |
|---|---|---|---|---|---|---|
| Cost of Revenue | 9.84 M | 5.21 M | 6.25 M | 5.83 M | 9.72 M | 8.91 M |
| Sequential Quarter Growth | +88.6% | -16.6% | +7.2% | -40.0% | +9.0% | +4,380.6% |
| Quarter-on Quarter Growth | +1.2% | -41.5% | +3,042.1% | +2,673.0% | +6,271.3% | +8,569.3% |
Annual Cost of Revenue values for Ascendis Pharma A/S are rounded to enhance readability
| 2022-Dec | 2022-Jan | 2021-Jan | 2020-Jan | 2019-Jan | 2018-Jan | |
|---|---|---|---|---|---|---|
| Cost of Revenue | 28.1 M | 28.1 M | 19.3 M | -5.45 M | 4.39 M | 11 M |
| Year-on-Year Growth | 0.0% | +45.5% | +454.3% | -224.1% | -59.9% | +480.3% |
| 2-yr CAGR | +20.6% | +109.7% | ||||
| 3-yr CAGR | +85.7% | +20.8% | ||||
| 4-yr CAGR | +59.1% | +26.6% | ||||
| 5-yr CAGR | +20.7% |
Frequency distribution of quarterly Cost of Revenue values from 2016-Sep-30 grouped into buckets. Latest Cost of Revenue value is 9.84 Million as of 2023-Mar-31
Subsequent stock performance post earnings date till next announcement for Ascendis Pharma A/S mapped with quarterly Cost of Revenue values reported at that time. Most recent value denoted with star
Select frequency and calculation type for Cost of Revenue above for vertical axis in scatter chart. Additionally choose type of performance for horizontal axis
Bayesian (Conditional Probability) analysis for Ascendis Pharma A/S with subsequent post-earnings performance given Cost of Revenue values. Analysis uses quarterly data and subsequent absolute performance. Most recent quarter is denoted with a star and corresponding partial performance is excluded from calculations
| Underperform (absolute perf.) | Outperform (absolute perf.) | |
|---|---|---|
| Cost of Revenue - Low | 36% | 64% |
| Cost of Revenue - Medium | 44% | 56% |
| Cost of Revenue - High | 63% | 38% |
| Cost of Revenue (Sequential growth %) - Low | 67% | 33% |
| Cost of Revenue (Sequential growth %) - Medium | 67% | 33% |
| Cost of Revenue (Sequential growth %) - High | 67% | 33% |
| Cost of Revenue (QoQ growth %) - Low | 100% | 0% |
| Cost of Revenue (QoQ growth %) - Medium | 50% | 50% |
| Cost of Revenue (QoQ growth %) - High | 50% | 50% |
Related to Ascendis Pharma A/S
Information for Ascendis Pharma A/S
Current Detail : Recent daily/monthly performance & benchmark comparison
Historical Detail : Historical performance & related information using Time Machine
Financial Statements : Analyze Income Statement, Balance Sheet & Cashflow Statement and also compare with peers Currently Viewing
Bayesian Statement Classifier : Investigate historical financial statements to make probabalistic predictions using Artificial Intelligence
Anomaly Detection : Investigate unusual recent performance & technicals with historical context using AI
Historical Seasonality : Seasonal performance by calendar months
Technical History : Popular Technical indicator trends (RSI, MACD etc.)
Metric Deciles : Contextualizing recent performance & technical levels into historical decile buckets
Dollar Cost Averaging : Dollar Cost Average (DCA) over time in your portfolio
Moving Averages : Key Simple & Exponential Moving Averages
Historical Analogues : Insights from closest historical matches to recent performance using Artificial Intelligence
Chart Pattern Matching : Insights from similar historical charts to recent chart using Artificial Intelligence
News Stories : News stories on 2024-Nov-13 on Google
SEC Reports : Quarterly reports around 2024-Nov-13 on SEC Edgar
Compare Ascendis Pharma A/S with other assets
Market Performance : Recent performance across covered assets
Historical Performance : Prior & Subsequent performance across assets on a historical date
Market Technicals : Technical indicator levels across covered assets
Market Seasonality : Seasonal performance by calendar months across covered assets
Pair Correlations : Performance Correlations with other assets
Beta : Volatility relative to the broad market
Performance Comparison : Visually compare/benchmark performance with other assets over time
Side-by-Side Comparison : Contrast with other assets over time in a side-by-side presentation
Sector : Health Care sector performance which includes Ascendis Pharma A/S
Industry : Pharmaceuticals industry performance which includes Ascendis Pharma A/S